The immediate objective of MagForce is to obtain European regulatory approval of its Nano-Cancer^® therapy to treat specific forms of tumors, then to obtain regulatory approval in the U.S., Japan and elsewhere, and ultimately to obtain approval to use it to treat all kinds of tumors. Regulatory approval requires successful completion of two clinical trials: a phase I study of feasibility, followed by a phase II study of efficacy in a larger patient group. On November 03, 2009 MagForce announced the successfull completion of its phase II study for the Nano-Cancer^® therapy. Please have a look at the graphic demonstrating the results. Please find further information on http://www.magforce.de